ArticleCureus2026
Presentation and Management of Progestogen Hypersensitivity in a Male Patient in the Emergency Department and Intensive Care Unit.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progestogen hypersensitivity (PH), historically termed autoimmune progesterone dermatitis, is an exceedingly rare condition documented almost exclusively in reproductive-age women. Although the pathophysiology remains incompletely understood, affected patients typically develop cutaneous and mucocutaneous findings, bronchospasm, and/or anaphylaxis following exposure to endogenous progesterone or exogenous progestins. Diagnosis rests on clinical history and characteristic physical findings, supported where available by progesterone skin testing, which is not standardized and has limited sensitivity and specificity. Cases in men are exceptionally rare, and the resulting scarcity of literature contributes to frequent misdiagnosis. We report a 56-year-old man with coronary artery disease, prior resection of an intestinal carcinoid tumor, and recurrent documented episodes of PH since 2006. He presented to the emergency department with a diffuse rash, facial angioedema, and nausea, and received intravenous fluids, epinephrine, antihistamines, and corticosteroids. Because his symptoms persisted and further epinephrine dosing was limited by chest pain in the setting of coronary artery disease, he was admitted to the intensive care unit for airway monitoring. Inpatient management consisted of dexamethasone, cromolyn sodium, testosterone cypionate, analgesia, and supportive care, with rapid improvement and discharge on hospital day three. This report describes a symptom-directed approach to the management of PH in a male patient in the critical care setting and considers the comorbidities and possible mechanisms that may underlie his presentation. Given the rarity of the condition and the limited literature in men, effective management currently depends on an individualized, symptom-directed strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.